Germany - Drugs

Description

Establishment of a DBS for the procurement of medicinal products of various indication groups in various dosage forms.The DBS is carried out in 2 phases:1. Establishment and management of a bidder poolThe DBS is established for the stated duration and range of services. The process will be conducted electronically only. The contracting authority shall establish a pool of bidders.Any interested party may activate participation in the procedure and submit a request to participate at any time during the DBS. Any interested party that meets the eligibility criteria published in the contract notice is included in the bidder pool. He thus becomes a potential bidder and may submit a bid in the subsequent individual awards.The bidder pool is not limited in size. Any qualified participant will be included in the bidder pool.2. Bidding PhaseActual procurements will be made in the form of individual awards as required by the contracting authority during the bidding phase. The contracting authority decides on the timing or number of individual awards. It is expressly pointed out that there is no obligation on the part of the contracting authority to carry out individual awards.On the occasion of the individual award, the contracting authority invites all participants in the bidder pool admitted to the DBS to submit a bid and informs them of the specific terms of the contract (e.g. quantity, delivery time, place of delivery, award criteria, etc.), provided these have not already been published in the notice.By submitting a bid, the bidder declares that no changes will be made to the suitability criteria. The content of the tenders received will be examined on the basis of the award criteria published. The bidder with the most economical bid to be determined on the basis of the notified award criteria will be awarded the contract.Participants admitted to the DBS bidder pool are not obliged to submit a bid in the context of the individual awards.Participants must always keep themselves informed of the current status of the award procedure (the individual award). Any extensions of deadlines, applicant questions with the corresponding answers or other updates and changes must be retrieved independently by the participant from the federal e-award platform. Any changes will be promptly announced by the contracting agency.
60,000,000 units It is intended to contract the following medicinal products, for example, within the framework of the DBS.The quantities stated (total time = term of the DBS; requirement 2021 = anticipated annual requirement 2021) represent forecast values in each case.It is expressly noted that additional active ingredients may be placed through individual awards.In addition, it is planned to prematurely terminate the DBS Antibiotics and the DBS Antidota, Corticoids, Narcotics, Analgesics and Anticoagulants on 31.12.2021 and to transfer them to the DBS at issue here on 1.1.2022.Legend: AM = Ampoule, EA = Piece, TU = Tube, BT = Bottle, TBL = Tablet, IE = International UnitCardiac drugs 1. Adenosine Injection (active ingredient Adenosine 6 MG/2ML), total requirement approx. 31 010 AM, requirement 2021 approx. 30 210 AM,2. Amlodipine Tablet (active ingredient Amlodipine 5 MG), total requirement approx. 907 000 EA, requirement 2021 approx. 2 400 EA, 3. Cafedrine and theodrenaline hydrochloride injection (active ingredient 1 cafedrine 200 MG, active ingredient 2 theodrenaline 10 MG), total requirement approx. 111,002 AM, requirement 2021 approx. 47,5624. Candesartancilexetil tablet (active ingredient candesartan 16 MG divisible) total requirement approx. 1,730,176 EA, requirement 2021 approx. 0 EA5. Metoprolol succinate extended release tablet (active ingredient metoprolol 39.91 MG divisible) Total requirement approx. 481,540 EA, requirement 2021 approx. 5,100 EA6. Ramipril tablet (active ingredient RAMIPRIL 2.5 MG), total requirement approx. 804,180 EA, requirement 2021 approx. 0 EA7. Ramipril Tablet (active ingredient RAMIPRIL 10MG) Total requirement approx. 168,200 EA, requirement 2021 approx. 3,600 EAAAntiemetics1. Dimenhydrinate Injection (active ingredient Dimenhydrinate 62 MG), total requirement approx. 31,220 AM, requirement 2021 approx. 29,040 AM2. Dimenhydrinate injection (active ingredient dimenhydrinate 100 MG, active ingredient 2 benzyl alcohol 105 MG) total requirement approximately 17,524 AM, requirement 2021 approximately 12,000 AM3. Dimenhydrinate tablets (active ingredient dimenhydrinate 50 MG) Total requirement approx. 1,700,000 EA, requirement 2021 approx. 1,940 EA4. Ondansetron hydrochloride injection (active ingredient ondansetron 4 MG) Total requirement approx. 46,485 AM, requirement 2021 approx. 12,025 AMOphthalmics1. Acetazolamide Tablet (active ingredient acetazolamide 250 MG) Total requirement approx. 93,930 EA, requirement 2021 approx. 90,130 EA2. Dexpanthenol ointment (active ingredient dexpanthenol 50 MG) Total requirement approx. 157,132 TU, requirement 2021 approx. 27,930 TU3. Sodium chloride solution (active ingredient sodium chloride 4.5 GM) Total requirement approx. 19,848 BT, requirement 2021 approx. 6,648 BT4. Oxybuprocaine hydrochloride eye drops (active ingredient oxybuprocaine 4 MG) Total requirement approx. 24,513 BT, requirement 2021 approx. 19,970 BTDermatika1. Aciclovir cream (active ingredient aciclovir 50 MG/G) Total requirement approx. 32,090 TU, requirement 2021 approx. 522 TU2. Dexpanthenol eye and nose ointment (active ingredient Dexpanthenol 50 MG/G) Total requirement approx. 157,132 TU, requirement 2021 approx. 27,930 TU3. Oily cream for the treatment of skin diseases on dry skin (active ingredient fatty acids, unsaturated 8.15 MG) Total requirement approx. 27,413 TU, requirement 2021 approx. 2,040 TU4. Miconazole nitrate _Flupredniden cream (active ingredient 1 Miconazole 1 MG, active ingredient 2 Flupredniden 0.9 MG) Total requirement approx. 15,023 TU, requirement 2021 approx. 4,890 TU Gastrointestinal therapeutics 1. Loperamide hydrochloride capsule (active ingredient Loperamide 1.860 MG) Total requirement approx. 851,473 EA, requirement 2021 approx. 260,200 EA2. Magaldrate suspension (active ingredient Magaldrate 1600 MG) Total requirement approx. 198,570 BG, requirement 2021 approx. 0 BG3. Pantoprazole sodium tablet (active ingredient pantoprazole sodium 1,5-water 45.110 MG) Total requirement approx. 7,512,528 EA, requirement 2021 approx. 46,020 EA4. Simeticon chewable tablets (active ingredient Dimeticon 40 MG) Total requirement approx. 274,260 EA, requirement 2021 approx. 0 EAColds 1. Cetylpyridinium chloride and Benzocaine lozenge (active ingredient 1 Cetylpyridinium 1.4 MG, active ingredient 2 Benzocaine 10 MG) Total requirement approx. 5,917,888 EA, requirement 2021 approx. 24,480 EA2. Myrtol capsules (active ingredient MYRTOL 300 MG) Total requirement approx. 2,593,640 EA, requirement 2021 approx. 48,400 EA3. Acetylcysteine tablet (active ingredient acetylcysteine 600 MG) Total requirement approx. 558,430 EA, requirement 2021 approx. 72,680 EABroncholytic antiasthmatics 1. Codeine phosphate tablet (active ingredient codeine 22.1 MG) Total requirement approx. 153,118 EA. Requirement 2021 approx. 50,400 EA2. Ipratropium bromide solution for a nebulizer (active ingredient ipratropium bromide 0.25 MG) Total requirement approx. 47,902 AM, requirement 2021 approx. 36,420 AM 3. Salbutamol aerosol (active ingredient salbutamol 1.25 MG) Total requirement approx. 178,150 EA, requirement 2021 approx. 73,350 EAantimycotics 1. Bifonazole cream (active ingredient bifonazole 10 MG) Total requirement approx. 10,000 TU, requirement 2021 approx. 0 TU2. Itraconazole capsule (active ingredient itraconazole 100 MG) Total requirement approx. 24,080 EA, requirement 2021 approx. 1,190 EA3. Terbinafine hydrochloride cream (active ingredient terbinafine 10 MG) Total requirement approx. 10,561 TU, requirement 2021 approx. 3,638 TUMand pharyngeal therapeutics 1. Chlorhexidine digluconate solution (active ingredient chlorhexidine 1.13 MG) Total requirement approx. 23,190 BT, requirement 2021 approx. 90 BT2. Chlorhexidine digluconate gel (active ingredient chlorhexidine digluconate 10 MG) Total requirement approx. 1,890 TU, requirement 2021 approx. 90 TU Diuretics 1. Furosemide sodium infusion (active ingredient furosemide 250 MG/25ML) Total requirement approx. 4,278 AM, requirement 2021 approx. 1,680 AM2. Furosemide sodium injection (active ingredient furosemide 20 MG/2ML) Total requirement approx. 121,870 AM, requirement 2021 approx. 53,950 AM3. Furosemide sodium injection (active ingredient furosemide 40 MG/4ML) Total requirement approx. 26,040 AM, requirement 2021 approx. 25,680 AM4. Hydrochlorothiazide tablets (active ingredient hydrochlorothiazide 12.5 MG) Total requirement approx. 480,000 EA, requirement 2021 approx. 0 EA1. Clonazepam injection Total requirement approx. 38,950 AM, requirement 2021 approx. 36,870 AM

Opportunity closing date

25 April 2025

Value of contract

to be confirmed